Cranberry and Gut Health in Crohn's Disease
This study is looking at whether a cranberry powder supplement can improve gut health in adults with Crohn's disease (CD). People with CD often have an imbalance in their gut bacteria, and cranberry compounds might help beneficial bacteria. You would be randomly assigned to take either cranberry powder or a placebo (an inactive powder) once daily for 10 weeks. The main goal is to see if the cranberry powder changes the amount of certain beneficial gut bacteria (butyrate-producing Clostridia species). To join, you need to be an adult with confirmed Crohn's disease, with moderate to severely impaired quality of life, and your CD activity should be lower than sCDAI<450. The current status of this study is unclear, and it plans to enroll 50 people.
- Study design
- This is a randomized, double-blind, placebo-controlled study involving 50 participants. This means participants are randomly assigned to one of two groups, and neither you nor the researchers will know if you are receiving the cranberry powder or the placebo.
- What's involved
- You would take a supplement daily for 10 weeks. You will also complete online questionnaires and provide blood, urine, and stool samples at four different times over a total of 15 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 15 weeks, which includes a follow-up period after the 10-week supplement use.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Cranberry and Gut Health in Crohn's Disease
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ana Maldonado-Contreras, PhD · PRINCIPAL_INVESTIGATOR · University of Massachusetts, Worcester
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in relative abundance of butyrate-producing Clostridia species, assessed with shotgun metagenomic sequencing and MetaPhlAn taxonomic profiling15 weeks
Stool samples will be collected at Baseline and during the intervention. DNA will be extracted and sequenced using paired-end shotgun metagenomics (2×150 bp). Taxonomic profiling will be performed with MetaPhlAn to quantify species-level relative abundance. The primary endpoint is the within-participant change in the summed relative abundance (%) of butyrate-producing Clostridia (clusters IV \& XIVa). For each participant, species-level abundances will be summed to create a composite (%). The primary analysis will compare mean change from Baseline to time points during the intervention between intervention and placebo groups, with results summarized as mean change and between-group differences with 95% CIs. The unit measure is relative abundance, %.